Pharminent

Propeller Health Expands Digital Health R&D Partnership with GSK

NewsThe Propeller platform has been used by patients and physicians in over 55 commercial programs across the United States.Contributed Author: Propeller HealthTopics: Biotech https://www.dddmag.com/news/2017/08/propeller-health-expands-digital-health-r-d-partnership-gsk

Filed under: R&D

Takeda begins new R&D link-up with Molecular Templates

Takeda is increasing its R&D investment in oncology with a collaboration with Texas biotech Molecular Templates. The Japanese
The post Takeda begins new R&D link-up with Molecular Templates appeared first on Pharmaphorum. https://pharmaphorum.com/news/takeda-begins-new-rd-link-molecular-templates/

Filed under: R&D

Eli Lilly licenses Adimab antibody discovery and optimization tech

Adimab, LLC is transferring its proprietary antibody discovery and optimization platform to Lilly research sites in San Diego and New York. http://www.outsourcing-pharma.com/Preclinical-Research/Eli-Lilly-licenses-Adimab-antibody-discovery-and-optimization-tech

Filed under: R&D

Parexel, Sanofi explore use of wearables in clinical trial

Six years after Pfizer’s landmark REMOTE trial, Parexel and Sanofi are teaming up in a pilot study to revisit the idea of using wearables in clinical trials. http://www.fiercebiotech.com/cro/parexel-sanofi-explore-use-wearables-clinical-trial

Filed under: R&D

Industry Pulse: R&D spending in charts

Biopharmas are always on the hunt for ever-elusive innovations, but some are better at allocating investment than others. Here are five charts showing how the industry spends on R&D.  http://www.biopharmadive.com/news/industry-pulse-biopharma-research-development-spending/443506/

Filed under: R&D

Scientist.com Raises $24M for “Pharma Markets” that Outsource R&D

San Diego’s Scientist.com set out in 2006 to disrupt part of the pharmaceutical business by providing an Amazon-like approach to the business of hiring contract research organizations (CROs). The company, which operates a network of online markets for outsourcing biomedical research services and supplies, has raised $24 million in a new round of venture funding. […] http://www.xconomy.com/san-diego/2017/05/15/scientist-com-raises-24m-for-pharma-markets-that-outsource-rd/

Filed under: R&D

Sanofi’s €250m AI-driven R&D collaboration for metabolic disease

Sanofi and Artificial Intelligence (AI)-driven Exscientia have announced a €250m ($271.9m) drug target research collaboration and licence option agreement.  http://www.outsourcing-pharma.com/Preclinical-Research/Sanofi-s-250m-AI-driven-R-D-collaboration-for-metabolic-disease

Filed under: R&D

Biopharma opening up to new ways of partnering on R&D

A report from Deloitte found the number of early-stage, science-focused collaborations to have increased rapidly over the past 10 years.  http://www.biopharmadive.com/news/biopharma-partnerships-research-discovery-deloitte-report/440914/

Filed under: R&D

Merck advances R&D strategy through unique development model with Avillion for Anti IL-17 A/F Nanobody

Merck, a leading science and technology company, today announced a development agreement with Avillion, a UK-based company focused on increasing R&D output through innovative models, for anti IL-17 A/F Nanobody®. Merck’s Anti IL-17 A/F Nanobody® is an investigational therapy which has completed Phase I development, and is expected to begin Phase II in plaque psoriasis in 2017. http://www.worldpharmanews.com/merckgroup/3878-merck-advances-r-d-strategy-through-unique-development-model-with-avillion-for-anti-il-17-a-f-nanobody

Filed under: R&D

AI helping us make smarter, faster decisions, says Novartis R&D chief

Novartis is trialling artificial intelligence (AI) in settings across drug discovery and drug development to help its scientists
The post AI helping us make smarter, faster decisions, says Novartis R&D chief appeared first on Pharmaphorum. http://pharmaphorum.com/news/ai-helping-us-says-novartis-rd-chief/

Filed under: R&D

More Lost Than Gained In Shifting R&D Forecasts

http://seekingalpha.com/article/4044864-lost-gained-shifting-r-and-d-forecasts

Filed under: R&D

As R&D returns take a hit, some pharmas are ramping up spending

BioPharma Dive will be publishing several articles in the coming weeks focusing on R&D spending and comparing the dependence of some pharmas on revenue from best-selling drugs. http://www.biopharmadive.com/news/as-rd-returns-take-a-hit-some-pharmas-are-ramping-up-spending/433063/

Filed under: R&D

Why Pharma Under-Values Novel R&D

New data on drug ramp rates could increase the financial attractiveness of “pioneer” projects. http://www.forbes.com/sites/frankdavid/2016/12/07/launch-curves/

Filed under: R&D

Elsevier’s R&D Solutions Welcomes Four Biotech Start-Ups to the Hive

NEW YORK, October 20, 2016 /PRNewswire/ — Incubator Participants Receive Complimentary Access to Elsevier’s Information Solutions to Accelerate Research in Early Drug Discovery and Development Elsevier, a world-leading provider of scientific, technical and medical… http://www.prnewswire.com/news-releases/elseviers-rd-solutions-welcomes-four-biotech-start-ups-to-the-hive-597725141.html

Filed under: R&D

The Power of the Cloud for Life Science R&D

“In the new world, it is not the big fish which eats the small fish, it’s the fast fish which eats the slow fish…” — Klaus Schwab, Founder/Executive Chairman, World Economic Forum Over the past decade, the nature of innovation has changed—even as the pace has substantially increased. One of the reasons has been the ability […] http://www.xconomy.com/boston/2016/10/19/the-power-of-the-cloud-for-life-science-rd/

Filed under: R&D

Charles River strategic partnership to populate R&D pipeline, shorten timelines

As part of the company’s continued growth, Charles River’s recent partnership with The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) will work to accelerate drug development. http://www.outsourcing-pharma.com/Preclinical-Research/Charles-River-strategic-partnership-with-Tri-I-TDI

Filed under: R&D

U.N. panel challenges market-based approach to drug R&D

LONDON (Reuters) – The world cannot rely solely on free markets to deliver medicines needed by billions of people in poor countries, so governments should commit to a legally binding convention to coordinate and fund research and development.

http://www.reuters.com/article/us-health-pharmaceuticals-un-idUSKCN11K19W

Filed under: R&D

Drugmakers revive R&D focus on long stagnant women’s health market

Fueled by innovation in new treatments, the underserved women’s health market has begun to turn the proverbial corner. What took it so long? http://www.mmm-online.com/drugmakers-revive-rd-focus-on-long-stagnant-womens-health-market/article/517662/

Filed under: R&D

Big Pharma eyes Bay Area, Boston expansions as it cuts R&D elsewhere

http://www.bizjournals.com/sanfrancisco/blog/biotech/2016/07/merck-mrk-cancer-immunotherapy-biologics-research.html

Filed under: R&D

Pfizer R&D Head Gives a Hint to How Pharma Companies Choose Which Drugs to Bet On

http://www.biospace.com/news_story.aspx?StoryID=423552&full=1

Filed under: R&D

Categories